The prognosis of head and neck squamous cell carcinoma (HNSCC) is largely based on disease stage. Despite improvements in treatment, recurrence rates are still considered high. Currently, disease progression or regression after curative treatment is monitored by clinical evaluation combined with flexible endoscopy and/or imaging. However, specificity of imaging is low due to the posttreatment effects. Detection of circulating tumor DNA (ctDNA) from blood samples of HNSCC patients is a minimally invasive technique that could lead to an earlier detection of recurrence. In addition, digital droplet PCR (ddPCR) could be used to sensitively detect these mutational targets. Future study on ctDNA using ddPCR in blood samples of HNSCC patients is r...
Liquid biopsy is a minimally invasive detection method for molecular biomarkers in body fluids which...
The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis and surv...
Detection of minimal residual disease in patients with cancer, who are in complete remission with no...
The prognosis of head and neck squamous cell carcinoma (HNSCC) is largely based on disease stage. De...
Head and neck cancers remain difficult to treat due to their aggressive biological behavior and deli...
Head and neck cancer (HNC) is currently the sixth most common solid malignancy, accounting for a 50%...
Developing non-invasive diagnostic tools in the field of head and neck oncology has been a challenge...
Head and neck cancers are the seventh most frequent malignancy worldwide, consisting of a heterogene...
The 5-year relative survival for patients with head and neck cancer, the seventh most common form of...
Liquid biopsies (LB) are emerging in the oncology field, with promising data as new diagnostic, prog...
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global heal...
Head and neck cancer is the sixth most common cancer worldwide. It remains one of the leading causes...
Background Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global healt...
BACKGROUND: During posttreatment surveillance of head and neck cancer patients, imaging is insuffici...
The molecular landscape of head and neck squamous cell carcinoma (HNSCC) harbors potentially actiona...
Liquid biopsy is a minimally invasive detection method for molecular biomarkers in body fluids which...
The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis and surv...
Detection of minimal residual disease in patients with cancer, who are in complete remission with no...
The prognosis of head and neck squamous cell carcinoma (HNSCC) is largely based on disease stage. De...
Head and neck cancers remain difficult to treat due to their aggressive biological behavior and deli...
Head and neck cancer (HNC) is currently the sixth most common solid malignancy, accounting for a 50%...
Developing non-invasive diagnostic tools in the field of head and neck oncology has been a challenge...
Head and neck cancers are the seventh most frequent malignancy worldwide, consisting of a heterogene...
The 5-year relative survival for patients with head and neck cancer, the seventh most common form of...
Liquid biopsies (LB) are emerging in the oncology field, with promising data as new diagnostic, prog...
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global heal...
Head and neck cancer is the sixth most common cancer worldwide. It remains one of the leading causes...
Background Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global healt...
BACKGROUND: During posttreatment surveillance of head and neck cancer patients, imaging is insuffici...
The molecular landscape of head and neck squamous cell carcinoma (HNSCC) harbors potentially actiona...
Liquid biopsy is a minimally invasive detection method for molecular biomarkers in body fluids which...
The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis and surv...
Detection of minimal residual disease in patients with cancer, who are in complete remission with no...